{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:08Z","timestamp":1761870308765,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.clml.2011.02.002","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T00:40:16Z","timestamp":1306111216000},"page":"336-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance"],"prefix":"10.1016","volume":"11","author":[{"given":"James R.","family":"Berenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Yellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Quiery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siu-Fun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Colbourn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Gravenor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Tiffany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.K.","family":"Shamasunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wirtschafter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.02.002_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib3","first-page":"290","article-title":"Benign and malignant monoclonal hypergammaglobulinemia (gammopathy)","volume":"100","author":"Waldenstr\u00f6m","year":"1970","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.clml.2011.02.002_bib4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib6","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib7","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib9","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2011.02.002_bib11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/bjc.1986.136","article-title":"Importance of quantitative histology of bone changes in monoclonal gammopathy","volume":"53","author":"Bataille","year":"1986","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2011.02.002_bib12","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/archinte.1975.00330020071009","article-title":"Pseudomyeloma","volume":"135","author":"Maldonado","year":"1975","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2011.02.002_bib14","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V90.9.3743","article-title":"Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen","volume":"90","author":"Pecherstorfer","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resorption parameters [carboxy terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/eji.1830230408","article-title":"Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy","volume":"23","author":"Gaillard","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clml.2011.02.002_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","article-title":"Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens","volume":"58","author":"Vejlgaard","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02230356","article-title":"Bone remodeling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma","volume":"15","author":"Laroche","year":"1996","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clml.2011.02.002_bib19","first-page":"461","article-title":"Gammopathies of indeterminant significance and osteoporosis: association or coincidence?","volume":"27","author":"Laroche","year":"1998","journal-title":"Presse Med"},{"key":"10.1016\/j.clml.2011.02.002_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1445-5994.2001.00055.x","article-title":"Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance","volume":"31","author":"Diamond","year":"2001","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2011.02.002_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/clinchem\/47.4.686","article-title":"Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis","volume":"47","author":"Woitge","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.clml.2011.02.002_bib22","first-page":"108","article-title":"Dual-energy x-ray absorptiometry in patients with multiple myeloma and benign gammopathies","volume":"14","author":"Laroche","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clml.2011.02.002_bib23","first-page":"171","article-title":"Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings","volume":"14","author":"Laroche","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clml.2011.02.002_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2011.02.002_bib25","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.02.002_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1470-2045(11)70008-0","article-title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial","volume":"12","author":"Berenson","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.02.002_bib27","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in multiple myeloma","volume":"2010","author":"Kristinsson","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2011.02.002_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"Berenson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib30","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/bmj.38376.401701.8F","article-title":"Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study","volume":"330","author":"Abrahamsen","year":"2005","journal-title":"Br Med J"},{"key":"10.1016\/j.clml.2011.02.002_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegrin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bone.2005.05.004","article-title":"Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis","volume":"37","author":"Felsenberg","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.clml.2011.02.002_bib35","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib36","doi-asserted-by":"crossref","first-page":"15593","DOI":"10.1200\/jco.2007.25.18_suppl.15593","article-title":"The effects of intermittent androgen deprivation therapy (ADT) and zoledronic acid administration on bone density in patients with prostate cancer","volume":"25","author":"Katznelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.002_bib37","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.002_bib38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.002_bib39","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.002_bib40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00223-008-9145-2","article-title":"The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance","volume":"82","author":"Pepe","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clml.2011.02.002_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)","volume":"147","author":"Bird","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib42","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.002_bib43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.1992.tb08245.x","article-title":"Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance","volume":"81","author":"Blade","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.002_bib45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4065\/82.4.428","article-title":"Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size","volume":"82","author":"Rosinol","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2011.02.002_bib46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.002_bib47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.002_bib48","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.02.002_bib49","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3324\/haematol.2009.013961","article-title":"The significance of monoclonal gammopathy of undetermined significance","volume":"94","author":"Kyle","year":"2009","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:41Z","timestamp":1761870101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S2152265011000243"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.02.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}